Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
Parkinson's Disease
About this trial
This is an interventional treatment trial for Parkinson's Disease
Eligibility Criteria
Inclusion Criteria: Patients must have completed the Week 26 visit of TVP 1012/133 (Visit 06) in accordance with the protocol. Women must be postmenopausal, surgically sterile, or using adequate birth control methods. Women of childbearing potential must have a negative pregnancy test at Baseline/Month 0. Patients must be willing and able to give informed consent. Exclusion Criteria: Serious or severe, test drug-related (probable or definite) adverse reaction in study TVP 1012/133. Premature discontinuation from study TVP 1012/133 for any reason. A clinically significant or unstable medical or surgical condition which would preclude safe and complete study participation. Such conditions may include cardiovascular, pulmonary, hepatic, renal, or metabolic diseases; or malignancies, as determined by medical history, physical exam, skin evaluation, laboratory tests, chest x-ray, or electrocardiogram (ECG).
Sites / Locations
- Margolin Brain Institute
- Rush - Presbyterian St. Luke's Medical Center
- Creighton University
- Long Island Jewish Medical Center
- University of Rochester
- Pennsylvania Hospital
Arms of the Study
Arm 1
Experimental
rasagiline mesylate
rasagiline mesylate 1 mg oral once daily